XIG: FHIR Resources

FHIR IG Statistics: FHIR Resources

Version: All | R2 | R2B | R3 | R4 | R4B | R5 | R6
Authority: All | hl7 | ihe | national
Realm: All | BNW | au | be | br | ca | ch | cl | cr | cz | de | dk | ee | eu | fi | fr | il | in | it | jp | kr | nl | no | nz | pl | se | sl | stt | tw | uk | us | uv | vn
View: All | Resource Profiles | Datatype Profiles | Extensions | Logical Models | CodeSystems | ValueSets | ConceptMaps

Resources - All Kinds

75,411 resources

By Version

R2: 0
R2B: 0
R3: 3,448
R4: 55,341
R4B: 3,134
R5: 13,264
R6: 224

By Authority

none: 25,640
hl7: 42,405
ihe: 1,382
national: 3,470
who: 2,514

By Realm

none: 22,398
au: 648
be: 387
br: 299
ca: 764
ch: 1,527
cl: 469
cr: 45
cz: 384
de: 2,066
dk: 1,474
ee: 276
eu: 1,253
fi: 87
fr: 1,545
il: 308
in: 163
it: 181
jp: 293
kr: 5
nl: 2,153
no: 26
nz: 79
pl: 83
se: 29
sl: 2
stt: 116
tw: 901
uk: 97
us: 19,481
uv: 17,592
vn: 107
other: 7

Start Prev Rows 48400 - 48600 Next

Package	Version	Identity	Name/Title	Status	Date	Realm	Auth
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.153	Vinorelbine Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.154	Gemcitabine Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.155	Docetaxel	active	2024-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.156	Pemetrexed Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.158	Vinblastine Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.160	ECOG Performance Status	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.161	ECOG Performance Status	active	2020-10	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.162	ECOG Performance Status	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.164	Karnofsky Performance Status	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.165	Carboplatin Injectable	active	2020-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.166	Paclitaxel	active	2024-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.168	Doxorubicin Injectable	active	2022-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.169	Irinotecan Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.179	Bevacizumab Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.181	Methotrexate	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.184	Breast Cancer	active	2022-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.185	Breast Cancer	active	2023-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.191	Cancer Stage II	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.192	Cancer Stage IIA	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.193	Cancer Stage IIB	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.194	Pertuzumab Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.196	Ixabepilone Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.197	Goserelin	active	2024-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.200	Epirubicin Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.202	Ramucirumab Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.204	Letrozole	active	2024-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.206	Exemestane	active	2024-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.209	Fluorouracil	active	2024-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.210	Capecitabine Oral	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.222	Aprepitant Oral	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.223	Fosaprepitant Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.255	Colorectal Cancer	active	2021-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.256	Colorectal Cancer	active	2021-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.257	Colorectal Cancer Chemotherapy	active	2023-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.280	Cancer Stage IA	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.281	Cancer Stage IB	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.286	Cancer Stage IIC	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.291	Positive Result	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.292	Negative Result	active	2015-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.300	Pathological N Stage N1C	active	2024-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.332	Daunorubicin Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.336	Palonosetron Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.341	External Beam Radiotherapy	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.349	Metastatic Cancer	active	2023-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.439	T Category	active	2018-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.440	N Category	active	2018-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.441	M Category	active	2018-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.442	TNM Stage Group	active	2018-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.449	Opioids	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.492	Pharmacological interventions for depression	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.535	Ovarian Cancer	active	2023-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.536	Ovarian Cancer	active	2023-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.537	Fallopian Tube Cancer	active	2022-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.539	Fallopian Tube Cancer	active	2022-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.541	Peritoneal Cancer	active	2022-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.542	Peritoneal Cancer	active	2023-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.547	Cancer Stage 1C	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.555	Gender Female	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.556	Gender Male	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.557	Pathological N Stage N3a	active	2024-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.558	Pathological N Stage N3b	active	2024-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.560	Rolapitant Oral	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.599	Obinutuzumab Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.600	Ofatumumab Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.602	Neurokinin 1 Receptor Antagonist	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.604	Serotonin Receptor Antagonist	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.61	Cetuximab Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.63	Panitumumab Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.81	Palonosetron Oral	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.88	Lung Cancer	active	2015-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.89	Lung Cancer	active	2023-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.95	M Stage M0	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.97	Pathological M Stage M1	active	2024-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.98	Pathological M Stage M1a	active	2024-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.99	Pathological M Stage M1b	active	2024-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1125.7	PROMIS Depression Assessment	active	2023-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.11	Sleep Apnea	active	2018-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.13	Septic Shock due to C. Diff	active	2019-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.15	Body Temperature	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.16	Diarrhea Potentially due to CDI	active	2019-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.17	Abdominal Distension	active	2019-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.18	Vomiting potentially due to CDI	active	2019-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.19	Ileus due to infection	active	2019-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.20	Clostridium difficile infection	active	2019-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.3	Radiation Therapy Indicators from CPT	active	2017-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.4	Diagnostic Radiology Surrounding Face and Sinus	active	2017-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.5	Ear Surgery Affecting the Tympanic Membrane	active	2017-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.6	Allergic Rhinitis Immunotherapy	active	2017-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.8	Radiology to Head and Sinus	active	2017-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.9	Immunotherapy For Allergic Rhinitis	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1136.63	Aortic Dissection or Ruptured Aortic Aneurysm	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.1	C2S Alcohol Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.11	C2S Amphetamine Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.12	C2S Cannabis Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.13	C2S Cannabis Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.14	C2S Cannabis Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.15	C2S Cannabis Use DIsorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.16	C2S Cocaine Use Disorder	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.17	C2S Cocaine Use Disorder	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.18	C2S Cocaine Use Disorder	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.19	C2S Hallucinogens	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.2	C2S Alcohol Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.20	C2S Hallucinogens	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.21	C2S Hallucinogens	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.22	C2S Hallucinogens	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.23	C2S HIV/AIDS Information Sensitivity	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.24	C2S HIV/AIDS Information Sensitivity	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.25	C2S HIV/AIDS Information Sensitivity	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.26	C2S HIV/AIDS Information Sensitivity	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.27	C2S HIV/AIDS Information Sensitivity	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.28	C2S Inhalants	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.29	C2S Inhalants	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.3	C2S Alcohol Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.30	C2S Inhalants	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.32	C2S Mental Health Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.33	C2S Mental Health Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.34	C2S Mental Health Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.35	C2S Mental Health Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.36	C2S Mental Health Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.38	C2S Opioids	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.39	C2S Opioids	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.4	C2S Alcohol Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.40	C2S Opioids	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.42	C2S Opioids	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.43	C2S Other Psychoactive Substance Use Disorder	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.44	C2S Other Psychoactive Substance Use Disorder	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.45	C2S Other Psychoactive Substance Use Disorder	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.46	C2S Sedative Hypnotic, or anxiolytic related disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.47	C2S Sedative Hypnotic, or anxiolytic related disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.48	C2S Sedative Hypnotic, or anxiolytic related disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.49	C2S Sexuality and reproductive health information sensitivity	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.5	C2S Alcohol Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.51	C2S Tobacco Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.52	C2S Tobacco Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.53	C2S Tobacco Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.54	C2S Tobacco Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.55	C2S Substance Use Information Sensitivity	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.56	C2S Substance Use Information Sensitivity	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.58	C2S Sensitive Categories	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.59	C2S Opioids	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.6	C2S Amphetamine Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.60	C2S HIV/AIDS information Sensitivity	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.65	Test C2S Alcohol Use Disorders	active	2019-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.67	Test C2S HIV/AIDS Information Sensitivity	active	2019-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.7	C2S Amphetamine Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.8	C2S Amphetamine Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.9	C2S Amphetamine Use Disorders	active	2016-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.10	Diphtheria (Tests for Corynebacterium diphtheriae by Culture and Identification Method)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1002	Tuberculosis (Tests for Mycobacterium species by Culture and Identification Method)	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1012	S. Typhi Infection (Disorders) (SNOMED)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1016	S. Paratyphi Infection (Disorders) (SNOMED)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1017	S. Typhi Infection (Tests for S. Typhi by Culture and Identification Method)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1021	Dark Urine (SNOMED)	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1022	Acute Onset [Qualifier Value] (SNOMED)	active	2024-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1024	Acute Viral Hepatitis (SNOMED)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1027	Sepsis [Septicemia] [Bacterial] [Unspecified Organism] (ICD10CM)	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1029	Listeriosis [Listeria species] (Organism or Substance in Lab Results)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1030	Meningitis [Unspecified Cause] (ICD10CM)	active	2023-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1032	Encephalitis [Unspecified Cause] (ICD10CM)	active	2023-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1033	Encephalitis [Unspecified Cause] (SNOMED)	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1035	Indeterminate or Equivocal Lab Result Value	active	2023-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1037	Smoking Status [Current Nonsmoker] (SNOMED)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1040	Organisms (Tests by Unspecified Method)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1041	Organisms (Tests by Culture and Identification)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1044	Candida auris Infection (Tests for Candida auris by Culture and Identification Method)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1045	Candida auris Infection (Tests for Candida auris Nucleic Acid)	active	2023-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1047	Parkinson’s disease (Disorders) (ICD10CM)	active	2024-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1048	Parkinson’s disease (Disorders) (SNOMED)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1049	Parkinsonism [Secondary] (ICD10CM)	active	2024-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1050	Parkinsonism [Secondary] (SNOMED)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1065	Consciousness [Decreased Level] (SNOMED)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1071	Drug Use [IV Evidence] (SNOMED)	active	2023-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1072	Miosis (SNOMED)	active	2024-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1076	Opioid Overdose and Poisoning (Tests for Opioids [Quantitative])	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1083	Rash [Pustular Vesicular] (SNOMED)	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1084	Salivary Gland Swelling [Unspecified Cause] (Disorders) (SNOMED)	active	2024-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1090	Syphilis [Congenital] (Disorders) (SNOMED)	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1091	Cataracts [Nonspecific]/Congenital glaucoma [Unspecified Cause] (SNOMED)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1092	Congenital heart disease (SNOMED)	active	2023-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1093	Hearing impairment (SNOMED)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1095	Microcephaly (SNOMED)	active	2024-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1096	Developmental delay (SNOMED)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1099	Congenital heart disease (ICD10CM)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1100	Hearing impairment (ICD10CM)	active	2023-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1104	Developmental delay (ICD10CM)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1106	Listeriosis (Tests for Listeria monocytogenes Nucleic Acid in Specimen from Normally Sterile Site)	active	2023-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.112	Tetanus (Disorders) (SNOMED)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1130	Tickborne Relapsing Fever (Tests for Borrelia hermsii/miyamotoi/parkerii/turicatae Nucleic Acid)	active	2024-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1131	Lyme Disease (Tests for Borrelia afzelii/garinii IgG Antibody by Immunoassay	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1138	Staphylococcus Aureus (Tests by Culture and Identification Method)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1139	VISA/VRSA (Tests for Vancomycin Resistance Gene)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1145	Resistant Lab Result Value	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1148	Tests for Vancomycin Susceptibility [Ord]	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1149	Proteinuria (Tests for Total Protein in 24H Urine)	active	2024-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.115	Mumps (Disorders) (SNOMED)	active	2023-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1150	Thrombocytopenia (Tests for Platelets [#/volume] in Blood)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1156	Staphylococcus aureus (Organism or Substance in Lab Results)	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1169	Chikungunya Virus Disease (Tests for Chikungunya virus Nucleic Acid)	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.117	Mumps (Disorders) (ICD10CM)	active	2024-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1146.1180	Chikungunya Virus Disease (Tests for Chikungunya Virus Antibody [Quantitative])	active	2024-06	us	hl7